Morepen Laboratories Limited has informed the Exchange regarding Re-appointment of Cost Auditors of the company
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Morepen Laboratories' Board approved multiple items at its May 26, 2026 meeting. The company posted standalone net profit of Rs. 6,605.75 lakhs on total income of Rs. 170,269 lakhs for FY26, while consolidated net profit after minority interest was Rs. 2,031.54 lakhs on total income of Rs. 182,700.56 lakhs. The Board recommended a final dividend of Rs. 0.20 per share for FY26, subject to shareholder approval at the AGM. Additionally, the second addendum to the Business Transfer Agreement with subsidiary Morepen Medipath Limited was approved, revising the 'Appointed Date' for transferring the Medical Devices Business to April 1, 2026, with slump sale consideration of Rs. 19,710.12 lakhs. Cost auditors M/s. Vijender Sharma & Co. were re-appointed for FY27.
The company's financial results show solid revenue but lower profitability versus prior year, while the Rs. 0.20 dividend provides shareholder returns. The business transfer of Medical Devices to the subsidiary represents an internal reorganization that may reshape the company's operational structure going forward.